Compass Therapeutics, Inc. Share Price OTC Markets
Equities
CMPX
US20454B1044
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.145 USD | -67.75% | +32.67% | 0.00% |
28/05 | Compass Therapeutics Appoints Thomas Schuetz as CEO | MT |
28/05 | Compass Therapeutics, Inc. Announces CEO Changes | CI |
Sales 2024 * | - | Sales 2025 * | 53.29L 44Cr | Capitalization | 17Cr 1.38TCr |
---|---|---|---|---|---|
Net income 2024 * | -5.4Cr -449.86Cr | Net income 2025 * | -7.1Cr -591.48Cr | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 31 x |
P/E ratio 2024 * |
-3.1
x | P/E ratio 2025 * |
-2.75
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.96% |
1 day | -67.75% |
Managers | Title | Age | Since |
---|---|---|---|
Thomas Schuetz
CEO | Chief Executive Officer | 63 | 01/14/01 |
Neil Lerner
DFI | Director of Finance/CFO | 56 | 01/20/01 |
Karin Herrera
CTO | Chief Tech/Sci/R&D Officer | - | 01/23/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Lindahl
BRD | Director/Board Member | 70 | 21/23/21 |
Mary Gray
BRD | Director/Board Member | 71 | 25/22/25 |
Ellen Chiniara
BRD | Director/Board Member | 65 | 25/22/25 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.95% | 12TCr | |
+19.51% | 11TCr | |
+18.95% | 2.65TCr | |
-24.07% | 1.94TCr | |
-19.03% | 1.62TCr | |
-21.13% | 1.54TCr | |
-46.14% | 1.52TCr | |
+63.85% | 1.49TCr | |
+4.39% | 1.35TCr |
- Stock Market
- Equities
- CMPX Stock
- CMPX Stock